Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

Summary

TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.

Timeline

Start

2021-06-01

Primary completion

2021-09-01

Completion

2021-09-01

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty in patient recruitment and will start again if study population increases to allow study feasibility”

Drugs

Indications